These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30567283)

  • 21. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
    Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
    Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood pemphigus foliaceus presenting as a polycyclic eruption: Case report and review of the literature.
    Evans MS; Culton DA; Diaz LA; Googe PB; Morrell DS
    Pediatr Dermatol; 2019 Mar; 36(2):236-241. PubMed ID: 30762246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Citrobacter freundii spondylitis and sickle cell disease: a case in Morocco].
    El Baaj M; Lazrak K; Tabache F; Hassikou H; Hadri L
    Med Trop (Mars); 2010 Aug; 70(4):387-9. PubMed ID: 22368940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
    Barrera MV; Mendiola MV; Bosch RJ; Herrera E
    J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
    Greenblatt DT; Benton EC; Groves RW; Setterfield JF
    Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rituximab induced remission of pemphigus vulgaris: 2 cases].
    Borel C; Launay F; Garrouste C; Astudillo L; Bazex J; Arlet P; Paul C; Viraben R; Sailler L
    Rev Med Interne; 2007 Apr; 28(4):266-8. PubMed ID: 17188405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
    El Tal AK; Posner MR; Spigelman Z; Ahmed AR
    J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sepsis in a renal transplant recipient due to Citrobacter braakii.
    Gupta R; Rauf SJ; Singh S; Smith J; Agraharkar ML
    South Med J; 2003 Aug; 96(8):796-8. PubMed ID: 14515921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment of Pemphigus Vulgaris With Ofatumumab.
    Rapp M; Pentland A; Richardson C
    J Drugs Dermatol; 2018 Dec; 17(12):1338-1339. PubMed ID: 30586270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Citrobacter freundii endocarditis].
    Clemente González C; Ruiz Aguirre J; Vilert Garrofa E; García Bragado F
    An Med Interna; 1999 Jul; 16(7):363-4. PubMed ID: 10481339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonpseudomonal ecthyma gangrenosum.
    Reich HL; Williams Fadeyi D; Naik NS; Honig PJ; Yan AC
    J Am Acad Dermatol; 2004 May; 50(5 Suppl):S114-7. PubMed ID: 15097944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of reported infectious events following rituximab therapy in pemphigus patients.
    Shahrigharahkoshan S; Dadkhahfar S; Mozafari N; Shahidi-Dadras M
    Dermatol Ther; 2022 Mar; 35(3):e15264. PubMed ID: 34907628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxical disease flare, skin infection and hypogammaglobulinaemia in patients with pemphigus vulgaris treated with rituximab.
    Padhiyar JK; Patel NH; Lakum MP; Patel JR; Patel KA; Patel HB; Chaudhary PB
    Clin Exp Dermatol; 2024 Jan; 49(2):175-177. PubMed ID: 37811867
    [No Abstract]   [Full Text] [Related]  

  • 36. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
    Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
    Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris - a systematic review.
    McClatchy J; Yap T; Koo K; Kern JS; Scardamaglia L
    Expert Opin Biol Ther; 2021 Dec; 21(12):1591-1601. PubMed ID: 34092162
    [No Abstract]   [Full Text] [Related]  

  • 39. A retrospective case-control study of clinical factors associated with paradoxical exacerbation of pemphigus vulgaris following rituximab infusion.
    Narayanan A; Ramam M; Bhari N
    Int J Dermatol; 2020 Dec; 59(12):e459-e460. PubMed ID: 33197052
    [No Abstract]   [Full Text] [Related]  

  • 40. Septic shock in a refractory pemphigus vulgaris patient after rituximab therapy.
    Lima RB; Manhães MB; de Souza Felix M; Gonçalves MLC
    Dermatol Ther; 2021 Jan; 34(1):e14725. PubMed ID: 33377269
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.